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Abstract 
Airway epithelial injury is regarded as a key contributing factor to the pathogenesis of 
exercise-induced bronchoconstriction (EIB) in athletes. The concentration of the 
pneumoprotein club cell (Clara cell) CC16 in urine has been found to be a non-invasive 
marker for hyperpnoea-induced airway epithelial perturbation. Exercise-hyperpnoea induces 
mechanical, thermal and osmotic stress to the airways. We investigated whether osmotic 
stress alone causes airway epithelial perturbation in athletes with suspected EIB. Twenty-four 
recreational summer sports athletes who reported respiratory symptoms on exertion 
performed a standard eucapnic voluntary hyperpnoea test with dry air and a mannitol test 
(osmotic challenge) on separate days. Median urinary CC16 increased from 120 to 310 
ρg·μmol creatinine
-1
 after dry air hyperpnoea (P = 0.002) and from 90 to 191 ρg·μmol 
creatinine
-1
 after mannitol (P = 0.021). There was no difference in urinary CC16 
concentration between athletes who did or did not bronchoconstrict after dry air hyperpnoea 
or mannitol. We conclude that, in recreational summer sports athletes with respiratory 
symptoms, osmotic stress per se to the airway epithelium induces a rise in urinary excretion 
of CC16. This suggests that hyperosmolarity of the airway surface lining perturbs the airway 
epithelium in symptomatic athletes. 
Word count: 193 
Keywords: asthma, exercise-induced bronchoconstriction, airway hyper-responsiveness, 
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Introduction 
Airway epithelium is the first barrier to the external environment and thus crucially important 
for the protection of the internal environment. In asthma, disruption of the epithelial barrier is 
regarded as one of the primary defects.
1
 Through detection of the pneumoprotein club cell 
(Clara cell) CC16 in extra-pulmonary fluids, strenuous exercise has recently been shown to 
transiently compromise the integrity of the airway epithelium.
2-5
  
 
Exercise-induced bronchoconstriction (EIB) is highly prevalent in individuals with asthma,
6
 
but can also be observed in otherwise healthy individuals without any other features of 
asthma.
7, 8
 Endurance athletes are particularly at risk for EIB.
9
 In this population, the 
mechanical stress imposed on the airways by sustained hyperpnoea combined with various 
environmental stimuli could create a ‘chronic wound scenario’, whereby repeated injury and 
repair of the airway epithelium leads to airway hyperresponsiveness (AHR).
10
  Further, 
during hyperpnoea of dry air the water lost by evaporation from the airway surface is 
replaced by water moving from the epithelial cells, so that the cells become shrunken and 
hyperosmolar.
11
 This change in height and osmolarity in the epithelial cell also occurs in 
response to a hyperosmolar challenge to the airway surface with mannitol.
12
 
 
Eucapnic voluntary hyperpnoea (EVH) of dry air is the recommended bronchial provocation 
challenge for EIB detection in elite athletes.
13
 In addition to mechanical stress, EVH causes 
both thermal and osmotic changes in the airways.  Osmotic challenge with inhaled mannitol 
has also been used as a surrogate for exercise to identify EIB.
14, 15
 
 
Bronchial provocation challenge with swimming, but not with mannitol has recently been 
associated with an increase in urinary CC16 concentration in young elite swimmers.
4
 Further, 
4 
 
in another study,
5
 serum concentration of CC16 increased after a 1500 m swimming session 
in well-trained young adult swimmers, but not after recreational pool attendance in children 
and adults. Taken together these findings suggest that the increased concentration of CC16 in 
extra-pulmonary fluids following strenuous exercise may be a consequence of mechanical 
stress on the airway epithelium rather than osmotic stress. Chlorinated by-products found in 
indoor swimming pools however have the capacity to disrupt the airway epithelium acutely
5
 
and may damage the club cells.
16
 Thus there is uncertainty regarding the respective role of 
mechanical stress and of osmotic stress on CC16 response during exercise-hyperpnoea in 
non-swimmers.    
 
The aim of our study was to investigate if urinary concentration of CC16 increased in 
response to an osmotic stimulus in recreational athletes not engaged in competitive 
swimming. To this end, urinary concentration of CC16 was measured in a group of 
recreational summer sport athletes with suspected EIB in two separate conditions: the first, 
following a 6-min EVH test, and the second, following inhalation of dry powder mannitol to 
cause the same degree of bronchoconstriction as EVH. Based on previous publications,
2, 4, 17
 
we proposed that an increase in urinary CC16 will be observed only following EVH.   
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Materials & methods 
Study population 
Twenty four recreational summer sports athletes who reported respiratory symptoms, such as 
cough, wheeze, breathlessness, chest tightness or mucus hyper-secretion, on exertion were 
recruited. Twelve of the participants had a previous physician diagnosis of asthma (two were 
diagnosed with childhood asthma only) and five had a previous physician diagnosis of EIB. 
None had had a bronchial provocation challenge done before. Five participants used inhaled 
corticosteroids (ICS) daily for at least 6 months (dosage: 400 to 1,000 mg beclomethasone 
daily or equivalent, including two on combination therapy) and another five used inhaled 
short-acting beta2-agonists (SABA) alone. All participants trained for a minimum of 3 h per 
week and most (92%) were taking part in some form of competition (but none represented 
their country at international sporting events). Exclusion criteria were: baseline forced 
expiratory volume in the first second (FEV1) <70% predicted, respiratory infection within the 
last month, current smokers, pregnant women, elite athletes and competitive swimmers. 
Participants refrained from caffeine− or alcohol−containing−drinks on the test days, and from 
exercise within 4 hours. ICS were withheld for 12 h, SABA for 8 h and long acting beta2-
agonists for 24 h. The study was approved by Brunel University Research Ethics Committee 
(RE21-08). All participants provided informed written consent. 
Study design 
Participants were asked to attend the laboratory between 08:00 and 09:30 h. They all 
completed two experimental visits separated by at least 48 hours, but less than 15 days. 
During the first visit, an EVH test and a skin prick test were carried out. During the second 
visit, a mannitol test was performed. During both visits urine samples were collected prior to 
and after bronchial provocation testing. 
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Spirometry 
Maximal forced vital capacity manoeuvres were carried out at baseline on a MicroLoop 
spirometer (MicroMedical, Cardinal Health, Basingstoke, UK) according to international 
guidelines.
18
 Predicted normal values were determined from established reference values.
19
 
EVH test 
The EVH challenge was performed on a EucapSys (SMTEC SA, Nyon, Suisse) according to 
standard recommendations
20
 Participants were required to breathe at a target ventilation rate 
of 30 times baseline FEV1 for 6 min while breathing in a dry air mixture at room temperature 
containing approx. 5% CO2, 21% O2 and balance N2. Forced vital capacity manoeuvres were 
performed in duplicate at 3, 5, 10, 15, 20, 30 and 60 min after the challenge and the best 
FEV1 value was recorded at each time point. A test was considered positive when a ³10% fall 
in FEV1 from baseline was documented over at least two consecutive time points. The % fall 
was used as index of reactivity of the airways. 
Mannitol test 
The mannitol test was performed according to the manufacturer’s instructions (Pharmaxis 
Ltd, French Forest, NSW, Australia).
21
 In participants negative to EVH, the mannitol 
challenge was stopped when a 15% decrease in FEV1 was measured, or when a total 
cumulative dose of 635 mg had been administered. In those positive to EVH, the mannitol 
challenge was stopped when the same fall in FEV1 was attained as during the first visit (all 
but one athlete had a ³15% fall in FEV1 post-EVH and for the athlete with a 14% fall in 
FEV1 post-EVH we aimed for a 15% in FEV1 during mannitol challenge), or when a total 
cumulative dose of 635 mg had been administered. A test was considered positive when the 
fall in FEV1 was ³15% from the 0 mg dose. The response was expressed as the provoking 
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dose of mannitol required to induce a 15% fall in FEV1 (PD15), an index of airway sensitivity. 
The response–dose ratio (RDR; final percentage fall FEV1 / total dose of mannitol 
administered), an index of airway reactivity, was also calculated. Following completion of 
the test, forced vital capacity manoeuvres were performed at the same time intervals as those 
after challenge with EVH. The best FEV1 value at each time point was used in the analysis. 
During the recovery period, FEV1 readings were compared to baseline to calculate the % fall 
in FEV1.  
Urinary CC16 
Participants were asked to drink 200 mL of water 1 h before arrival. At commencement of the 
study visits, participants emptied their bladder and provided a baseline urine sample. Post 
bronchial provocation testing, urine samples were collected at 30 and 60 min. After each 
urine collection, 200 mL of water was provided. All samples were stored without addition of 
preservatives at minus 80°C and were analysed within two months.
22
 CC16 was measured 
using the Human Clara Cell Protein ELISA kit from BioVendor (Modrice, Czech Republic) 
according to the manufacturer’s protocol. The detection limit for CC16 was 20 ρg×ml
-1
. All 
samples were analyzed for creatinine using a COBAS 6000 System analyser (Roche 
Diagnostics) to correct results for dilution.  
Atopic status 
In eighteen athletes skin prick tests were carried out using standardized allergen extract 
(ALK, Abello, UK) of house dust mite, timothy grass and cat hair, together with a positive 
and negative control. A reaction with a wheal of ³3 mm in diameter was considered a 
positive test for atopy. In the first six participants allergens extracts were not available at the 
time of testing. 
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Data analysis 
Sample size requirements were calculated using the data from our previous study;
 2
 for an 
alpha of 5% and a beta of 10%, it was expected that at least 21 participants would be needed 
to detect a reduction of 60% in the rise in urinary CC16 after mannitol compared to after 
EVH. Athletes were grouped a posteriori as AHR
+
 (for those positive to EVH and / or 
mannitol) or AHR
-
 (for those negative to both EVH and mannitol). CC16 results are 
presented as peak versus baseline, with the peak value as the highest value observed at 30 or 
60 min after bronchial provocation challenge. The areas under the time curve (AUC) for 
CC16 and FEV1 were calculated from the absolute and relative changes from baseline 
respectively, during the 60-min observation period after both challenges by using the 
trapezoidal method. Between-group comparisons were carried out using unpaired t-tests, 
Mann Whitney tests (for non-parametric variables) or Fishers’ exact test (for binomial 
variables). Urinary CC16 data were not normally distributed. Therefore, within-group 
comparisons were carried out using Friedman or Wilcoxon tests. Spearman’s rank correlation 
test was used to check for relationships between study variables. All statistical calculations 
were performed using SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL). Values are means ± 
SD, unless otherwise stated. The level of significance was set at P < 0.05.  
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Results 
Participant characteristics 
Twelve participants trained in endurance sports, six in team sports, two in combat sports, 
three in trampolining / aerobics, and one in rock climbing. Anthropometric, training and 
baseline lung function data were similar between athletes AHR
+
 and AHR
-
 (Table 1).  
Airway response to EVH and mannitol 
Eleven athletes (46%) were positive with a sustained 10% fall after EVH. One athlete had a 
non-sustained bronchoconstriction (maximum fall in FEV1 of 10% at 10 min recovery only) 
and was classified as EVH negative. The fall in FEV1 for the EVH positive group was 25 ± 
12% (versus 7 ± 2% in the EVH negative group, P < 0.001). The ventilation achieved by 
athletes positive and negative to the test was similar (96 ± 15 versus 100 ± 16 L·min
-1
) and 
was equivalent to 78 ± 6 and 81 ± 10% pred. maximal voluntary ventilation (calculated as 35 
times baseline FEV1), respectively. 
Eight athletes (33%) were positive to mannitol with an FEV1 fall of 21 ± 13% (versus 4 ± 3% 
in negative group, P = 0.001), a PD15 of 254 ± 169 mg, and a RDR of 0.066 ± 0.035%·mg
-1
 
(versus 0.005 ± 0.007%·mg
-1
 in the negative group, P = 0.002). Three athletes positive to 
EVH did not reach the 15% threshold after inhaling 635 mg of mannitol. A strong association 
was found between airway reactivity to mannitol expressed as the RDR mannitol and airway 
reactivity to dry air hyperpnoea expressed as % fall in FEV1 post-EVH (rs = 0.738, P < 
0.001). 
Within each study group (athletes AHR
+
 and AHR
-
) the maximal fall in FEV1 during the 
recovery period and FEV1-AUC were similar between visits (data not shown). Out of the 
fifteen athletes with current physician-diagnosed asthma and / or EIB, eight (53%) did not 
have AHR (two of whom were prescribed ICS). Two athletes with physician-diagnosed 
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childhood asthma were positive to EVH and mannitol. Out of the five athletes using ICS 
daily for at least 6 months, three still had demonstrable AHR. Three out of five athletes using 
inhaled SABA alone also still had demonstrable AHR. 
Urinary CC16 
Three participants AHR
-
 had urinary CC16 concentrations below detection limits during both 
tests and were excluded from the CC16 statistical analysis. Two participants AHR
+
 had 
urinary CC16 concentrations below detection point during one visit only (one during the 
EVH visit and one during the placebo visit); their CC16 values during the alternative visits 
were kept for analysis. Urinary CC16 data at each time point and the magnitude of change 
post-challenges did not significantly differ between AHR
+
 and AHR
-
 athletes. Therefore all 
CC16 results are presented for the study population as a whole. 
Baseline urinary CC16 was similar between the two study visits (Table 2). Both bronchial 
provocation tests caused an increase in urinary excretion of CC16, as shown by the 
statistically significant difference (P < 0.05) between the peak CC16 concentration post-
challenges and baseline values (Fig. 1.). No significant difference in the magnitude of change 
in urinary CC16 was observed between challenges (Table 2). However, over the time-course 
of recovery, urinary CC16 showed a significant increase both at 30 min (P = 0.003) and 60 
min (P = 0.006) post-EVH, whilst it failed to reach significance after mannitol (Fig. 2). There 
was also a trend for CC16–AUC to be greater after EVH compared to mannitol (P = 0.059) 
(Table 2).  
Significant correlations were found between CC16 values after EVH and mannitol: for peak 
CC16 rs was 0.668 (P = 0.002), for delta CC16 rs was 0.568 (P = 0.011) and for CC16–AUC 
rs was 0.556 (P = 0.013). However, no significant association was found between the 
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maximal fall in FEV1 post-challenges and the urinary release of CC16. Furthermore, the 
release of CC16 post-mannitol did not correlate with the total dose of mannitol inhaled. 
12 
 
Discussion 
The main aim of this study was to establish whether urinary concentration of the 
pneumoprotein club cell CC16 was increased after challenge with an osmotic stimulus in 
recreational summer sports athletes with suspected EIB. Inhaled mannitol was used because, 
like eucapnic voluntary hyperpnoea, it has been used as a surrogate for exercise to identify 
EIB.
14
 The concentration of urinary CC16 increased after both EVH and mannitol bronchial 
provocation challenges. This suggests that hyperosmolarity of the airway surface lining per 
se perturbs the functioning of the airway epithelium in symptomatic athletes. 
That dry air hyperpnoea leads to an increase in urinary excretion of CC16 confirms our prior 
findings.
2, 17
 In one study we demonstrated that breathing warm humid air during exercise 
reduced, but did not completely inhibit the increase in urinary CC16 post-exercise.
2
 Those 
findings suggested that, alongside mechanical stress, the thermal and osmotic effects of 
evaporative water loss during hyperpnoea also play a role in perturbing the airway 
epithelium. We now extend these findings by reporting that the osmotic challenge mannitol 
per se induces an increase in urinary excretion of CC16. This differs from the urinary CC16 
data that were previously obtained post-mannitol in swimmers.
4
 In that study, elite youngster 
swimmers had an increase in urinary CC16 one hour after completion of a swimming test, but 
not after mannitol. Alongside the possible confounding effect of chlorination by-products on 
CC16 data,
5, 16
 differences such as age of the participants,
23, 24
 level of competition and urine 
collection times could have contributed to the divergence with our current findings.  
One limitation of our study is that the population was heterogeneous in terms of medical 
history and pharmacological treatment. Whilst we acknowledge that asthma and EIB are two 
distinct entities, EIB is highly prevalent in asthmatic individuals.
6
 Furthermore, all our 
participants with a physician diagnosis of asthma reported exercise-related respiratory 
symptoms, which are suggestive of EIB. The diversity of medical history ensured that our 
13 
 
population was representative of the athletic population that commonly consult primary care 
for respiratory disorders, and allowed us to draw some conclusion about the appropriateness 
of using mannitol to help with the diagnosis of asthma / EIB in recreational summer sports 
athletes. In keeping with studies performed in elite summer sports athletes (non-swimmers)
14
 
and in non-athletic mild asthmatics,
25
 mannitol had a very high specificity (100%) to detect a 
positive response to EVH. The sensitivity of mannitol to identify those positive to EVH was 
however lower (73%), which suggests that in recreational summer sports athletes not engaged 
in competitive swimming mannitol may be better used to rule-in (rather than to rule-out) the 
presence of AHR to dry air. We cannot exclude that the long-term use of ICS may have 
modified club cell biology
26
 and / or integrity of the airway epithelium.
27
 Following removal 
in our statistical analysis of the five steroid-treated participants, the significant increase in 
urinary CC16 remained for both bronchial provocation challenges. Therefore, it is unlikely 
that ICS usage compromised our overall results.  
In our study, the sequence of the challenges was intentional to match the severity of 
bronchoconstriction for EVH and mannitol, and to avoid differences in local shear 
deformations and pressure gradients through mucosal folding.
28
 This was critical in that the 
airway epithelium is thought to play a prominent role in transducing mechanical stresses to 
nearby mesenchymal cells
29
 and, therefore, in activating mediator release.
30
 Unfortunately, 
we were not in a position to run an extra bronchial provocation challenge with methacholine, 
which would have helped to establish the role of airway narrowing per se on epithelial 
perturbations in athletes.     
That urinary CC16 increased after both challenges suggests that, in addition to mechanical 
stress, an increase in osmolarity is a contributing stimulus for CC16 changes observed after 
EVH. There was no association between the total dose of mannitol administered and the 
release of urinary CC16 post-challenge, a finding that suggests that sensitivity of the 
14 
 
epithelium to the osmotic stimulus is more important to CC16 release than is dose. CC16 is 
thought to play a role in reducing inflammation of the airways.
31
 Both EVH and mannitol are 
associated with the release of inflammatory mediators.
32-34
 For this reason we believe that the 
increase in urinary CC16 post-challenges was due, at least partly, to an inflammatory-
mediated increase in production / secretion of CC16 by the club cells. Alternatively, the post-
challenge increases in urinary CC16 may be explained by an increased leakage of the protein 
into the bloodstream following permeability changes of the airway epithelium.
35
 Changes in 
ventilation pattern
36
 and pulmonary pressure
37
 have been shown to increase airway epithelial 
permeability. Moreover, in conditions of airflow-related shear stress, injury and even death of 
epithelial cells may occur.
38
 During EVH, transient airway epithelial injury could therefore 
have facilitated the passage of CC16 from the airways to the bloodstream
17
 and contributed to 
the rise of CC16 in urine. 
Many athletes routinely engage in sports associated with high ventilatory demands, and often 
do so in cold dry environments. In these conditions, small airways are likely to be exposed to 
inadequately conditioned air, which may favour the release of inflammatory mediators of 
bronchoconstriction.
39
 Furthermore, as club cells are mainly localised in the distal airways,
40
 
CC16 is more likely to be released when small airways get dehydrated. The EVH test, which 
requires the use of a dry gas mixture and sets up a high target ventilatory flow for the 
participants, is particularly well-suited to cause dehydration to the small airways. Hyperpnoea 
with dry air has previously been shown to reduce mucociliary clearance in both the proximal 
and the peripheral airways.
41
 Mannitol, however, is thought to have greater effect on the 
osmolarity of the proximal airways.
42
 A regional difference in the dehydration stress induced 
in our study may therefore have contributed to a different level of stimulation of the club 
cells, and may explain i) the lack of significant increase in CC16 at 30 and 60 min post-
mannitol and ii) the trend for a greater CC16-AUC after EVH compared to mannitol.    
15 
 
In elite endurance athletes the risk for asthma, AHR and EIB is significantly increased.
9
 
Moreover, airway remodelling (a direct marker of  injury-repair) has been observed in elite 
cross-country skiers
43
 and in elite swimmers.
24
 It is therefore tempting to speculate that, 
similarly to the ‘chronic wound scenario’ proposed for the pathogenesis of asthma in the 
general population,
1
 elite athletes expose their airways to repeated mechanical, thermal and 
osmotic stresses that cause disruption of the airway epithelium and lead to structural and 
functional changes.  
 
In conclusion, this study showed an increase in the concentration of urinary CC16 both after 
EVH and mannitol bronchial provocation challenges in recreational summer sports athletes 
who report respiratory symptoms on exertion. It is therefore likely that hyperosmolarity of 
airway surface lining contributes to the increase in CC16 following dry air hyperpnoea in 
symptomatic athletes. This strengthens the viewpoint that osmotic changes associated with 
the conditioning of large volumes of air during strenuous exercise can cause damage to the 
airway epithelium.
10
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Figure captions 
Fig. 1. Club cell (Clara cell) protein (CC16) measured in urine before and after eucapnic 
voluntary hyperpnoea (a) and mannitol challenge (b) in recreational summer sports athletes 
with respiratory symptoms on exertion. ‘Peak’ are the highest values recorded over the 60-
min recovery period. Individual values with medians (interquartiles).  
 
Fig. 2. Mean ± SEM urinary excretion of club cell (Clara cell) protein (CC16) in 
symptomatic recreational summer sports athletes at baseline and over a 60-min period after 
eucapnic voluntary hyperpnoea (EVH) and mannitol challenge.  
 
Table 1. General characteristics of the study population 
 All athletes AHR
+
 AHR
-
 
N (males) 24 (12) 11 (5) 13 (7) 
Age (yr) 28 ± 8 27 ± 7 29 ± 10 
Height (cm) 172 ± 9 170 ± 9 175 ± 9 
Mass (kg) 73.8 ± 12.6 74.2 ± 15.5 73.4 ± 10.1 
Weekly training (h) 7 ± 3 7 ± 3 7 ± 4 
Training history (yr) 10 ± 8 9 ± 8 10 ± 9 
FEV1 (L) 3.54 ± 0.57 3.54 ± 0.58 3.54 ± 0.59 
FEV1 (% predicted) 
FVC (L) 
95 ± 11 
4.72 ± 0.86 
98 ± 12 
4.76 ± 0.78 
93 ± 10 
4.69 ± 0.95 
FVC (% predicted) 
FEV1/FVC (%) 
108 ± 12 
75 ± 7 
113 ± 14 
75 ± 8 
104 ± 9 
76 ± 7 
FEF25-75 (L·sec
-1
) 
FEF25-75 (% predicted) 
3.03 ± 0.85 
69 ± 18 
3.00 ± 0.93 
68 ± 19 
3.06 ± 0.81 
69 ± 17 
Physician diagnosis of asthma/EIB [N (%)] 
IBA use [N (%)] 
ICS use [N (%)] 
Atopy [N
+
/N total (%)] 
17 (71%) 
10 (42%) 
5 (21%) 
12/18 (67%) 
9 (82%) 
6 (55%) 
3 (27%) 
6/7 (86%) 
8 (62%) 
4 (31%) 
2 (15) 
6/11 (55%) 
Values are means ± SD or N (%). AHR
+
, athletes with airway hyper-responsiveness to dry air 
and / or mannitol; AHR
-
, athletes without airway hyper-responsiveness to dry air and 
mannitol; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; 
FEF25-75, forced expiratory flow between 25 and 75% of FVC; EIB, exercise-induced 
Table1_doc
bronchoconstriction; IBA, inhaled beta2-agonists; ICS; inhaled corticosteroids; N
+
, number of 
athletes with atopy. Between-group comparisons were not statistically significant. 
Table 2. Changes in airway calibre and in urinary club cell (Clara cell) protein 16 
concentration after bronchial challenge with eucapnic voluntary hyperpnoea (EVH) of dry air 
or mannitol in 24 symptomatic recreational summer sport athletes (11 with airway hyper-
responsiveness). 
 EVH Mannitol 
FEV1 values   
Maximal fall of FEV1, % 10 (7;27) 9 (6;26) 
FEV1–AUC, %·min 339 (189;616) 238 (169;507) 
Urinary CC16, ρg·mmol creatinine
-1
   
Baseline (pre-challenge) 113 (43;242) 87 (44;201) 
30 min post-challenge 239 (114;573)
**
 146 (72;275)
 
 
60 min post-challenge 305 (80;666)
**
 186 (86;297)
a
 
Peak post-challenge 305 (124;666)
**
 186 (100;342)
*
 
Pre- to peak post-challenge (delta) 250 (39;435) 80 (4;198) 
CC16–AUC, ρg·mmol creatinine
-1
·min 6250 (1095;13211) 1860 (-308;5528)
b
 
Values are medians (inter-quartile ranges); FEV1, forced expiratory volume in the first 
second; AUC, area under the curve; CC16, club cell (Clara cell) protein 16. Urinary CC16 
did not significantly differ between athletes with and without airway hyper-responsiveness, 
therefore data from both groups are presented together. 
*
 P < 0.05, 
**
 P < 0.01, significantly 
different from baseline; 
a
 P = 0.079 compared to baseline; 
b
 P = 0.059, compared to EVH. 
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